LL-37 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of LL-37 is rapidly degraded by proteases; major clinical limitation. This means dosing topical or local application as needed is typical to maintain stable levels. The half-life directly affects how long LL-37 remains active and influences optimal injection timing.
What Is the Half-Life of LL-37?
The half-life of LL-37 is rapidly degraded by proteases; major clinical limitation. This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer LL-37 to maintain therapeutic blood levels.
What Does LL-37's Half-Life Mean for Dosing?
With a half-life of rapidly degraded by proteases; major clinical limitation, LL-37 requires dosing topical or local application as needed to maintain stable levels. The standard dosage of 100-500 mcg (topical/local application) via topical wound application, local injection, intranasal accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, LL-37 reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For LL-37, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject LL-37?
Optimal timing depends on your research goals. A half-life of rapidly degraded by proteases; major clinical limitation means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (topical or local application as needed) for more stable levels throughout the day.
How Does LL-37's Half-Life Compare to Similar Peptides?
LL-37 is a Antimicrobial peptide, host defense peptide. Its half-life of rapidly degraded by proteases; major clinical limitation positions it with a longer duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your LL-37 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for LL-37.
Open Calculator →Bottom Line: LL-37 Half-Life and Dosing
LL-37 has a half-life of rapidly degraded by proteases; major clinical limitation, supporting the standard protocol of 100-500 mcg (topical/local application) dosed topical or local application as needed over acute use as needed.
Read our LL-37 dosage guide for complete protocol details.
Complete Guide
LL-37 : Benefits, Dosage, Side Effects & Research
Related Reading
- LL-37 Dosage Guide
- LL-37 Benefits
- LL-37 Side Effects
- LL-37 Stacking Guide
- LL-37 Cycle Guide
- LL-37 Research
Research-Grade Sourcing
If you're going to research LL-37, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What is the recommended LL-37 dosage?
Common dosages: 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal. Cycle length: acute use as needed. Half-life: rapidly degraded by proteases; major clinical limitation. Use our peptide calculator for exact reconstitution math.
What are the side effects of LL-37?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Is LL-37 safe?
LL-37 has shown a preliminary safety profile in research. Not FDA-approved as therapeutic. Research compound. Derivatives in late-stage clinical trials. All research should follow appropriate safety protocols.